Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on February 7, 2023. The report addresses a specific corporate event regarding the company's listing status on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing requirements rather than financial performance.
Material Changes
- Nasdaq Listing Status: The company previously received notice on February 18, 2022, that its common stock closing bid price had been below the $1.00 minimum requirement for 30 consecutive business days.
- Resolution: On February 7, 2023, the Nasdaq Office of General Counsel notified the company that the minimum bid price deficiency had been cured.
- Outcome: Nasdaq determined to continue the listing of the company's common stock on The Nasdaq Capital Market.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or new risk factors. The primary risk addressed was the potential delisting due to low stock price, which has been resolved as of the report date. A press release dated February 8, 2023, is included as an exhibit.
Investor Verification Checklist
- Verify the current trading price of JAGX to ensure it remains above the $1.00 minimum bid price requirement.
- Review the press release (Exhibit 99.1) for any additional details on the steps taken to cure the deficiency.
- Monitor future 8-K filings for any recurrence of listing deficiency notices.